1. Insights
  2. Blogs
  3. Eye on FDA

FDA Names the First Nine National Priority Voucher Recipients

October 23, 2025

Reading Time : 2 min

By: Anna K. Abram, Nathan A. Brown, Olive Lee

On October 16, 2025, the Food and Drug Administration (FDA) unveiled the first group of nine voucher recipients under the Commissioner’s National Priority Voucher (CNPV) pilot program, a program announced by the agency earlier this year that provides a path for accelerated drug review for companies supporting national interests as determined by the Commissioner. The identified areas of priority by the agency include meeting large unmet medical needs, bolstering domestic manufacturing and increasing the affordability of medicines for American patients. As previously noted, the new program, which is not defined in statute or regulations, aims to significantly speed up FDA’s standard 10-12 month review timeline to just 1-2 months after filing an application for a drug or biologic. The agency has touted the  benefit of recipients of the vouchers receiving enhanced access with FDA review staff and a “team-based review” model.

The nine voucher recipients span sponsors developing treatments related to infertility (Pergoveris), Type I diabetes (Teplizumab), nicotine vaping addiction (Cytisinicline), deafness (DB-OTO), blindness (Cenegermin-bkbj), pancreatic cancer (RMC-6236), and porphyria (Bitopertin). The first cohort announced by the agency also includes sponsors seeking to increase domestic drug manufacturing (ketamine, for general anesthesia, and Augmentin XR, a common antibiotic).

In announcing the first nine sponsors to receive the CNPV the agency reiterated that the awarding of the vouchers does not guarantee any regulatory outcome. The agency also provided additional insight into the CNPV selection process, noting that each drug review division within the agency was charged with nominating a product that they believe meets the stated goals of the program in addition to sponsors having the opportunity to apply for a voucher. While it is not clear how many total CNPVs will be awarded, FDA also noted in its announcement that the agency intends to announce additional CNPV recipients in the coming month, indicating additional vouchers are forthcoming. As with any new program or incentive that has the potential to accelerate drug development and review timelines, the interest in the agency’s implementation of the program will continue as additional details are made available.

Share This Insight

Categories

Lobbying & Public PolicyPolicy & RegulationPharmaceuticalsHealth CarePolicyRegulatoryFood and Drug Administration (FDA)Biologics
Subscribe to the Eye on FDA Blog Series >

Previous Entries

Eye on FDA

February 3, 2026

On February 1, 2026, the Food and Drug Administration (FDA) officially started accepting requests to participate in the FDA PreCheck pilot program. The goal of the program is to strengthen the domestic pharmaceutical supply chain by making the review and inspection process more predictable for U.S.-based drug manufacturing facilities.

...

Read More

Eye on FDA

January 28, 2026

The Food and Drug Administration (FDA) has begun 2026 with a clear signal to the direct‑to‑consumer testing industry: self‑collection devices remain firmly within the agency’s regulatory reach, notwithstanding the 2025 court ruling on laboratory developed tests (LDTs). Last week, the agency published warning letters previously issued to four companies—Genetrace, Genovate, Germaphobix and ProDx Health—selling human immunodeficiency virus (HIV) tests that rely on unauthorized self‑collection kits.

...

Read More

Eye on FDA

January 7, 2026

On January 6, the Food and Drug Administration (FDA) updated its guidance documents on Clinical Decision Support (CDS) software and general wellness products, and withdrew its guidance on the adoption of international principles for Software as a Medical Device (SaMD): Clinical Evaluation. FDA’s policy changes lean toward a more deregulatory approach to digital health, including enforcement discretion for certain prediction software, and exemption of certain wearables with non-invasive monitoring from FDA regulation.

...

Read More

Eye on FDA

December 22, 2025

On December 18, 2025, the Food and Drug Administration (FDA) released a final guidance entitled “Processes and Practices Applicable to Bioresearch Monitoring Inspections.” The guidance was issued to comply with the Food and Drug Omnibus Reform Act of 2022, which directs FDA to issue guidance describing the processes and practices applicable to inspections of sites and facilities inspected under FDA’s Bioresearch Monitoring (BIMO) inspection program, to the extent that is not covered in already available FDA guides and manuals. The BIMO program was established to assess and monitor the conduct and reporting of FDA-regulated research as well as postmarketing activities through on-site inspections, investigations and Remote Regulatory Assessments.

...

Read More

© 2026 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.